ASPIRA PATHLAB & DIAGNOSTICS | CHOKSI LAB. | ASPIRA PATHLAB & DIAGNOSTICS / CHOKSI LAB. |
|||
---|---|---|---|---|---|
P/E (TTM) | x | -13.4 | 13.6 | - | View Chart |
P/BV | x | 2.6 | 2.2 | 116.2% | View Chart |
Dividend Yield | % | 0.0 | 0.0 | - |
ASPIRA PATHLAB & DIAGNOSTICS CHOKSI LAB. |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
ASPIRA PATHLAB & DIAGNOSTICS Mar-23 |
CHOKSI LAB. Mar-23 |
ASPIRA PATHLAB & DIAGNOSTICS / CHOKSI LAB. |
5-Yr Chart Click to enlarge
|
||
High | Rs | 75 | 54 | 138.9% | |
Low | Rs | 26 | 25 | 104.1% | |
Sales per share (Unadj.) | Rs | 14.0 | 49.4 | 28.4% | |
Earnings per share (Unadj.) | Rs | -0.1 | 4.6 | -1.9% | |
Cash flow per share (Unadj.) | Rs | 1.5 | 12.5 | 11.6% | |
Dividends per share (Unadj.) | Rs | 0 | 0 | - | |
Avg Dividend yield | % | 0 | 0 | - | |
Book value per share (Unadj.) | Rs | 12.4 | 30.3 | 40.9% | |
Shares outstanding (eoy) | m | 10.29 | 6.97 | 147.6% | |
Bonus / Rights / Conversions | 0 | 0 | - | ||
Price / Sales ratio | x | 3.6 | 0.8 | 450.5% | |
Avg P/E ratio | x | -583.7 | 8.5 | -6,840.0% | |
P/CF ratio (eoy) | x | 34.6 | 3.1 | 1,100.0% | |
Price / Book Value ratio | x | 4.1 | 1.3 | 313.1% | |
Dividend payout | % | 0 | 0 | - | |
Avg Mkt Cap | Rs m | 518 | 274 | 189.1% | |
No. of employees | `000 | NA | NA | - | |
Total wages/salary | Rs m | 56 | 120 | 46.6% | |
Avg. sales/employee | Rs Th | 0 | 0 | - | |
Avg. wages/employee | Rs Th | 0 | 0 | - | |
Avg. net profit/employee | Rs Th | 0 | 0 | - |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 145 | 344 | 42.0% | |
Other income | Rs m | 3 | 2 | 147.9% | |
Total revenues | Rs m | 148 | 347 | 42.6% | |
Gross profit | Rs m | 16 | 125 | 12.7% | |
Depreciation | Rs m | 16 | 55 | 28.8% | |
Interest | Rs m | 4 | 35 | 11.9% | |
Profit before tax | Rs m | -1 | 37 | -2.4% | |
Minority Interest | Rs m | 0 | 0 | - | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
Tax | Rs m | 0 | 5 | 0.0% | |
Profit after tax | Rs m | -1 | 32 | -2.8% | |
Gross profit margin | % | 11.0 | 36.4 | 30.3% | |
Effective tax rate | % | 0 | 13.7 | -0.0% | |
Net profit margin | % | -0.6 | 9.3 | -6.6% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 59 | 139 | 42.0% | |
Current liabilities | Rs m | 16 | 125 | 12.7% | |
Net working cap to sales | % | 29.5 | 4.2 | 711.0% | |
Current ratio | x | 3.7 | 1.1 | 331.6% | |
Inventory Days | Days | 88 | 4 | 2,059.8% | |
Debtors Days | Days | 590 | 1,129 | 52.3% | |
Net fixed assets | Rs m | 115 | 455 | 25.2% | |
Share capital | Rs m | 103 | 70 | 147.8% | |
"Free" reserves | Rs m | 25 | 141 | 17.4% | |
Net worth | Rs m | 128 | 211 | 60.4% | |
Long term debt | Rs m | 10 | 236 | 4.1% | |
Total assets | Rs m | 173 | 595 | 29.2% | |
Interest coverage | x | 0.8 | 2.1 | 38.3% | |
Debt to equity ratio | x | 0.1 | 1.1 | 6.7% | |
Sales to assets ratio | x | 0.8 | 0.6 | 144.0% | |
Return on assets | % | 1.9 | 11.3 | 16.7% | |
Return on equity | % | -0.7 | 15.2 | -4.6% | |
Return on capital | % | 2.4 | 16.2 | 14.8% | |
Exports to sales | % | 0 | 3.5 | 0.0% | |
Imports to sales | % | 0 | 0 | - | |
Exports (fob) | Rs m | NA | 12 | 0.0% | |
Imports (cif) | Rs m | NA | NA | - | |
Fx inflow | Rs m | 0 | 12 | 0.0% | |
Fx outflow | Rs m | 0 | 1 | 0.0% | |
Net fx | Rs m | 0 | 11 | 0.0% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 0 | 83 | -0.1% | |
From Investments | Rs m | 2 | -7 | -22.5% | |
From Financial Activity | Rs m | -9 | -76 | 12.3% | |
Net Cashflow | Rs m | -8 | -1 | 1,125.7% |
Indian Promoters | % | 18.7 | 31.5 | 59.5% | |
Foreign collaborators | % | 0.0 | 0.0 | - | |
Indian inst/Mut Fund | % | 0.0 | 0.0 | - | |
FIIs | % | 0.0 | 0.0 | - | |
ADR/GDR | % | 0.0 | 0.0 | - | |
Free float | % | 81.3 | 68.5 | 118.6% | |
Shareholders | 1,512 | 4,187 | 36.1% | ||
Pledged promoter(s) holding | % | 0.0 | 0.0 | - |
Compare ASPIRA PATHLAB & DIAGNOSTICS With: APOLLO HOSPITALS DR. LAL PATHLABS METROPOLIS HEALTHCARE KIMS NARAYANA HRUDAYALAYA
No comparison is complete without understanding how the stock prices have performed over a period of time.
Here's a brief comparison:
Period | ASPIRA PATHLAB & DIAGNOSTICS | CHOKSI LAB. | S&P BSE HEALTHCARE |
---|---|---|---|
1-Day | -2.14% | 1.99% | 0.45% |
1-Month | -8.93% | 58.17% | 2.55% |
1-Year | -3.33% | 47.80% | 56.14% |
3-Year CAGR | 1.86% | 100.84% | 15.22% |
5-Year CAGR | -1.91% | 37.79% | 19.63% |
* Compound Annual Growth Rate
Here are more details on the ASPIRA PATHLAB & DIAGNOSTICS share price and the CHOKSI LAB. share price.
Moving on to shareholding structures...
The promoters of ASPIRA PATHLAB & DIAGNOSTICS hold a 18.7% stake in the company. In case of CHOKSI LAB. the stake stands at 31.5%.
To review how promoter stakes have changed over time, and how much of the promoter stake is pledged, please see the shareholding pattern of ASPIRA PATHLAB & DIAGNOSTICS and the shareholding pattern of CHOKSI LAB..
Finally, a word on dividends...
In the most recent financial year, ASPIRA PATHLAB & DIAGNOSTICS paid a dividend of Rs 0.0 per share. This amounted to a Dividend Payout ratio of -0.0%.
CHOKSI LAB. paid Rs 0.0, and its dividend payout ratio stood at 0.0%.
You may visit here to review the dividend history of ASPIRA PATHLAB & DIAGNOSTICS , and the dividend history of CHOKSI LAB..
For a sector overview, read our pharmaceuticals sector report.
After opening the day on high, Indian share markets reversed the trend as the session progressed and ended the lower.